<!DOCTYPE html>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title>Cobometyx</title>
	<link rel="stylesheet" href="style/css/style.css">
</head>
<body>
	<header class="page-header">
		<div class="page-header__logo">
			<img src="style/img/pimgpsh_fullsize_distr.png">
		</div>
		<div class="page-nav">
			<div class="page-nav__logo">
			</div>
			<ul class="nav-menu">
				<li class="nav-menu__item item-1">
					<a href="" class="nav-menu__link active">
						<span>Overview</span>
					</a>
				</li>
				<li class="nav-menu__item item-2">
					<a href="" class="nav-menu__link">
						<span>Clinical</span>
					</a>
				</li>
				<li class="nav-menu__item item-3">
					<a href="" class="nav-menu__link">
						<span>Monograph</span>
					</a>
				</li>
			</ul>
			<div class="nav-menu__button">
				<span></span>
				<span></span>
				<span></span>
			</div>
		</div>
	</header>
	<div class="container">
		<div class="section-1">
			<div class="section-1__main-logo"></div>
			<p class="section-1__main-description">CABOMETYXTM is now approved in patients who have received prior therapy* for advanced renal cell carcinoma (RCC)<sup>1</sup> <br>
				<span class="black-text">*Anti-angiogenic therapy.</span>
			</p>
		</div>
		<div class="section-2">
			<div class="section-2__title">
				<h1 class="section-2__sub-title">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Category 1 Recommendation2</h1>
				<p class="section-2__description">Cabozantinib (CABOMETYXTM) has a Category 1 recommendation for patients with advanced clear cell histology RCC after prior anti-angiogenic therapy.</p>
				<div class="section-2__flying-molecule"></div>
			</div>
			<div class="section-2__content">
				<div class="first-block">
					<p class="first-block__description">
						CABOMETYXTM is the only single agent to demonstrate significant improvement across 3 endpoints—overall survival (OS), progression-free survival (PFS), and objective response rate (ORR)—in advanced RCC after prior treatment1*<br>
						<span class="black-text">*Anti-angiogenic therapy.</span>
					</p>
					<img class="first-block__logo" src="style/img/page-1(1).png">
				</div>
				<div class="second-block">
					Based on the results of the METEOR trial,1 the NCCN Guidelines® include cabozantinib (CABOMETYXTM) as a Category 1 subsequent therapy option in patients with advanced clear cell RCC who have been previously treated with anti-angiogenic therapy, and note that eligible patients should preferentially receive it over everolimus.
					<sup>2</sup>
				</div>
				<div class="third-block">
					<img class="third-block__logo" src="style/img/group-2.png">
					<div class="third-block__text-wrapper">
						<h1 class="third-block__title">quick start program</h1>
						<p class="third-block__description">Eligible patients receive a 15-day supply at no cost</p>
						<ul class="third-block__list">
							<li class="third-block__list-item">Available for new patients who experience a delay of more than 5 days in the processing or approval of their prescription for CABOMETYX™</li>
						</ul>
					</div>
				</div>
			</div>
		</div>
		<div class="section-3">
			<div class="section-3__title">
				<div class="section-3__title-logo"></div>
				<div class="section-3__title-logo section-3__title-logo--company"></div>
				<div class="section-3__title-molecule1"></div>
				<div class="section-3__title-molecule2"></div>
				<div class="section-3__title-molecule3"></div>
			</div>
			<div class="section-3__content">
				<ul class="section-list">
					<li class="section-list__item"> 
						<span class="section-list__item-title"><img src="style/img/briefcase-69.png" alt="">company:</span>
						<span class="section-list__item-content">Exelixis®</span>
					</li>
					<li class="section-list__item"> 
						<span class="section-list__item-title"> <img src="style/img/molecule-10.png" alt="">pharmacologic <br>class:</span>
						<span class="section-list__item-content">Receptor tyrosine kinase inhibitor</span>
					</li>
				</ul>
			</div>
		</div>
		<footer class="page-footer">
			<div class="page-footer__download-block">
				<a href="#"><img src="style/img/down-arrow-56.png">Download Alert</a>
			</div>
			<div class="page-footer__input-block">
				<h1>Would you like additional information?</h1>
				<form>
					<input type="text" placeholder="Enter your email">
					<input type="submit" value="Submit">
				</form>
			</div>

			<div class="page-footer__list-block">
				<h1>Additional Links:</h1>
				<ul class="nav-list">
					<li class="nav-list__item"><a href="#">Visit CABOMETYX™ Website</a></li>
					<li class="nav-list__item"><a href="#">Download Dosing and</a></li>
					<li class="nav-list__item"><a href="#">Administration Guide</a></li>
					<li class="nav-list__item"><a href="#">Download Patient Q&A</a></li>
					<li class="nav-list__item"><a href="#">Access EASE Enrollment Form</a></li>
				</ul>
			</div>
		</footer> 
	</div>
	<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.1.1/jquery.min.js"></script>
	<script>
		$(function() {
			$('.nav-menu__button').click(function() {
				$('.page-nav').toggleClass('open')
			})
		})
	</script>
</body>

